Laboratory Animal and Comparative Medicine ›› 2026, Vol. 46 ›› Issue (2): 306-310.DOI: 10.12300/j.issn.1674-5817.2026.004
• Expert Voices • Previous Articles
Received:2026-01-04
Revised:2026-03-26
Online:2026-04-25
Published:2026-04-18
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.slarc.org.cn/dwyx/EN/10.12300/j.issn.1674-5817.2026.004
| [1] | 孙强. 无替代,何谈取消[J]. 实验动物与比较医学, 2025, 45(3): 376-378. DOI: 10.12300/j.issn.1674-5817.2025.064 . |
| [2] | 孙强. 非动物实验替代知多少[J]. 实验动物与比较医学, 2025, 45(4): 508-514. DOI: 10.12300/j.issn.1674-5817.2025.117 . |
| [3] | 孙强. 类器官不是器官[J]. 实验动物与比较医学, 2025, 45(5): 649-654. DOI: 10.12300/j.issn.1674-5817.2025.148 . |
| [4] | 孙强. TG 497视角下动物实验完全替代的突破与困境[J]. 实验动物与比较医学, 2025, 45(6): 810-812. DOI: 10.12300/j.issn.1674-5817.2025.133 . |
| [5] | 孙强. FDA新政下减少非人灵长类实验动物使用量的可行路径[J]. 实验动物与比较医学, 2026, 46(1): 149-152. DOI: 10.12300/j.issn.1674-5817.2025.213 . |
| [6] | U.S. Food and Drug Administration. Generic Drugs Undergo Rigorous FDA Review[EB/OL]. (2022-09-16)[2026-01-02]. https://www.fda.gov/consumers/consumer-updates/generic-drugs-undergo-rigorous-fda-review. |
| [7] | BLOSSOM D B, KALLEN A J, PATEL P R, et al. Outbreak of adverse reactions associated with contaminated heparin[J]. N Engl J Med, 2008, 359(25): 2674-2684. DOI: 10.1056/NEJMoa0806450 . |
| [8] | HUECKER M R, SMILEY A, SAADABADI A. Bupropion[M/OL]//StatPearls. Treasure Island (FL): StatPearls Publishing, 2024-09-02)[2026-01-02]. https://www.ncbi.nlm.nih.gov/books/NBK470212/. |
| [9] | U.S. Food and Drug Administration. Update: Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies[EB/OL]. (2014-10-02)[2026-01-02].https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/update-bupropion-hydrochloride-extended-release-300-mg-bioequivalence-studies. |
| [10] | SINCLAIR L. Generic bupropion product withdrawn from market[J]. Psychiatr News, 2012, 47(21): 4-17. DOI: 10.1176/pn.47.21.psychnews_47_21_4-a . |
| [11] | SEDLO I, KOLONIĆ T, TOMIĆ S. Presence of nitrosamine impurities in medicinal products[J]. Arh Hig Rada Toksikol, 2021, 72(1): 1-5. DOI: 10.2478/aiht-2021-72-3491 . |
| [12] | FARRUKH M J, TARIQ M H, MALIK O, et al. Valsartan recall: global regulatory overview and future challenges[J]. Ther Adv Drug Saf, 2019, 10: 2042098618823458. DOI: 10.1177/2042098 618823458 . |
| [13] | U.S. Food and Drug Administration. FDA updates and press announcements on angiotensin Ⅱ receptor blocker (ARB) recalls (valsartan, losartan, and irbesartan)[EB/OL]. (2019-11-13)[2026-01-02]. . |
| [14] | CENZIPER D, ROSE M. The FDA often doesn't test generic drugs for quality concerns, so ProPublica did[EB/OL]. (2025-12-22)[2026-01-02]. https://www.propublica.org/article/fda-generic-drug-testing. |
| [15] | Association for Accessible Medicines. 2025 U.S. generic & biosimilar medicines savings report[R/OL]. [2026-01-02]. https://accessiblemeds.org/resources/reports/2025-savings-report/. |
| [16] | Commission European. EudraLex Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use[EB/OL]. (2022-02-21)[2026-01-02]. https://health.ec.europa.eu/latest-updates/eudralex-volume-4-eu-guidelines-good-manufacturing-practice-medicinal-products-human-and-veterinary-2022-02-21_en. |
| [17] | U.S. Food and Drug Administration. Intas Pharmaceuticals Ltd. Intas Pharmaceuticals Limited[EB/OL]. (2023-08-01)[2026-01-02]. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-652067-07282023. |
| [18] | ADASHI E Y, O'MAHONY D P, COHEN I G. The FDA Modernization Act 2.0: drug testing in animals is rendered optional[J]. Am J Med, 2023, 136(9): 853-854. DOI: 10.1016/j.amjmed.2023.03.033 . |
| [19] | U.S. Food and Drug Administration. FDA Announces Plan to Phase out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs[EB/OL]. (2025-04-10)[2026-01-02]. https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs. |
| [20] | 孙强. 为什么要开展动物实验[J]. 实验动物与比较医学, 2024, 44(1): 121-126. DOI: 10.12300/j.issn.1674-5817.2023.177s . |
| [1] | PAN Linqin, DENG Xiangliang, LUO Yunxia. Advances in Integrative Translational Research on Animal Models of Ischemic Stroke in Traditional Chinese and Western Medicine [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 344-356. |
| [2] | GAO Yilong, HE Xingliang, ZHOU Xiaopeng, LI Dawei, BAO Xijun, LI Laiyou. Mining Candidate Genes for Litter Size Traits in English Springer Spaniel Bitches Based on Whole Genome Resequencing [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 378-387. |
| [3] | WANG Juan, XU Jiahui, TIAN Yunyuan, ZHANG Mengmeng, LI Min, WANG Siwang, LI Yao. Comparison and Behavioral Observation of Two Female Mice Models of Ulcerative Colitis [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 332-343. |
| [4] | CHEN Bing, XIE Xiaojie, TAO Tifu, WANG Jingdong, ZOU Yixing. Research on the Current Situation and Countermeasures for Training and Education of Laboratory Animal Practitioners in Sichuan Province [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 456-463. |
| [5] | TANG Jianping, ZHAO Liya, ZHAO Ying. Screening and Analysis of Microsatellite Genetic Markers in Commonly Used Inbred Rat Strains [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 388-396. |
| [6] | BU Yu, HOU Jinting, LI Yuanyuan, SHA Jingtao, XIE Chenlu, WANG Wengang, SUN Xingwei. A Review and Evaluation of Integrated Disease and Syndrome Animal Models for Hemorrhoids in Traditional Chinese and Western Medicine [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 357-366. |
| [7] | BU Jiwen, HUA Ye, JIN Shirong, REN Ningxin, LI Funing, DU Jiulin. Automated Management of Zebrafish Strains and Zebrafish Facilities [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 416-425. |
| [8] | WANG Xiuran, LI Hao, CHEN Zhengtao, YU Yang, ZHANG Suying, TAO Ru, WANG Kezhou. Innovation and Practice in the Construction of "Three-in-one" Talent Training Systems for Laboratory Animal Professionals in Medical Colleges [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 446-455. |
| [9] | LI Jiafei, ZHANG Zhenhao, WANG Shuo, TIAN Ge, WEN Shuang, YAN Yuxue, CUI Ran, YE Zhen, CUI Yongchun. Effects of Autonomic Neuromodulators on Atrial Electrical Remodeling and Histopathological Changes in a Rat Model of Atrial Fibrillation [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 321-331. |
| [10] | CHEN Lin, ZHANG Housen, AI Man, QI Chongyang. Research on the High-Quality Development Path of Laboratory Animal Management in Jiangsu Province Empowered by Digital Transformation [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 426-436. |
| [11] | LI Longxue, WAN Chongfan, ZHANG Qi, LEI Ruting, WANG Xiaoyue, CHENG Leyan, LAI Qi, LIU Ronghua, LIU Xuan, XU Tielong. Molecular Mechanisms of Qingfei Paidu Decoction in the Prevention and Treatment of Acute Lung Injury in Mice Based on miRNA Sequencing [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 311-320. |
| [12] | AI Xiufeng, ZHANG Lizong, FANG Mingsun, LÜ Dongying, CHEN Chu, CAI Zhaowei, WANG Dejun. Analysis of Differences in the Intestinal Flora of Rats and Mice after Drinking Chlorinated Water Based on 16S rRNA Sequencing [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 437-445. |
| [13] | ZHOU Yimin, ZHANG Xinyu, YANG Jianuo, LIU Mengjia, SI Cancan, YE Hailü, SUN Wenchao, LAN Tian. Development of a Triplex TaqMan Quantitative PCR Method for Simultaneous Detection of MHV, MPV, and Reo-3 [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 408-415. |
| [14] | . [J]. Laboratory Animal and Comparative Medicine, 2026, 46(3): 464-466. |
| [15] | WANG Lu, WANG Qingjie, YANG Chunhong, ZHANG Yijian. The Application of New Approach Methodologies in the Biomedical Field and Its Implementation of "3R" Principle [J]. Laboratory Animal and Comparative Medicine, 2026, (): 1-10. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
